

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10568367
Filing Date	2006-08-18
First Named Inventor	Carlos GARCIA-ECHEVERRIA
Art Unit	1624
Examiner Name	2344
Attorney Docket Number	PAT032910B-US-PCT

**U.S.PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5958935		1999-09-28	Davis et al.	
	2	6093716		2000-07-25	Davis et al.	
	3	6114333		2000-09-05	Davis et al.	
	4	6048866		2000-04-11	Hutchings et al.	
	5	7671063		2010-03-02	Baenteli et al.	
	6	7514446		2009-04-07	Davis-Ward et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>	Application Number		10568367	
	Filing Date		2006-08-18	
	First Named Inventor		Carlos GARCIA-ECHEVERRIA	
	Art Unit		1624	
	Examiner Name		2344	
	Attorney Docket Number		PAT032910B-US-PCT	

	1	20060100227	A1	2006-05-11	Baenteli et al.	
	2	20060247241	A1	2006-11-02	Garcia-Echeverria et al.	
	3					

If you wish to add additional U.S. Published Application citation information please click the Add button.

#### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2004056786	WO	A1	2004-07-08	Pfizer Products Inc.		<input type="checkbox"/>
	2	2006068770	WO	A1	2006-06-29	Rigel Pharmaceuticals, Inc.		<input type="checkbox"/>
	3	2002056888	WO	A2	2002-07-25	Novartis AG		<input type="checkbox"/>
	4	1998041512	WO	A1	1998-09-24	Celltech Therapeutics Limited		<input type="checkbox"/>
	5	2001025220	WO	A1	2001-04-12	Kinetix Pharmaceuticals Inc.		<input type="checkbox"/>
	6	2005026130	WO	A1	2005-03-24	Novartis AG		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>		Application Number	10568367
		Filing Date	2006-08-18
		First Named Inventor	Carlos GARCIA-ECHEVERRIA
		Art Unit	1624
		Examiner Name	2344
		Attorney Docket Number	PAT032910B-US-PCT

	7	2005016894	WO	A1	2005-02-24	Novartis AG	<input type="checkbox"/>
--	---	------------	----	----	------------	-------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	TRAXLER, Peter M. , "Protein Tyrosine Kinase Inhibitors in Cancer Treatment", Expert Opinion on Therapeutic Patents, Vol. 7, No. 6, pp. 571-588, 1997.	<input type="checkbox"/>
	2	SIMONE et al., Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, Vol. 1, pp. 1004-1010, 1997.	<input type="checkbox"/>
	3	BASFORD et al., CAPLUS Abstract 41:763, pp. 7810-7812, 1947.	<input type="checkbox"/>
	4	COOPMAN et al., "The Syk Tyrosine Kinase Suppresses Malignant Growth of Human Breast Cancer Cells", Nature, Vol. 406, pp. 742-747, August 17, 2000.	<input type="checkbox"/>
	5	USPTO Final Office Action mailed May 20, 2010, of pending U.S. Patent Application No. 10/549,250 (U.S. Patent Publication No. 2006/0247241).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.